FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011518421> ?p ?o ?g. }

• W3011518421 endingPage "433.e14" @default.
• W3011518421 startingPage "433.e1" @default.
• W3011518421 abstract "Background Many cases of placenta accreta spectrum are not diagnosed antenatally, despite identified risk factors and improved imaging methods. Identification of plasma protein biomarkers could further improve the antenatal diagnosis of placenta accreta spectrum . Objective The purpose of this study was to determine if women with placenta accreta spectrum have a distinct plasma protein profile compared with control subjects. Study Design We obtained plasma samples before delivery from 16 participants with placenta accreta spectrum and 10 control subjects with similar gestational ages (35.1 vs 35.5 weeks gestation, respectively). We analyzed plasma samples with an aptamer-based proteomics platform for alterations in 1305 unique proteins. Heat maps of the most differentially expressed proteins (T test, P<.01) were generated with matrix visualization and analysis software. Principal component analysis was performed with the use of all 1305 proteins and the top 21 dysregulated proteins. We then confirmed dysregulated proteins using enzyme-linked immunosorbent assay and report significant differences between placenta accreta spectrum and control cases (Wilcoxon-rank sum test, P<.05). Results Many of the top 50 proteins that significantly dysregulated in participants with placenta accreta spectrum were inflammatory cytokines, factors that regulate vascular remodeling, and extracellular matrix proteins that regulate invasion. Placenta accreta spectrum, with the use of the top 21 proteins, distinctly separated the placenta accreta spectrum cases from control cases (P<.01). Using enzyme-linked immunosorbent assay, we confirmed 4 proteins that were dysregulated in placenta accreta spectrum compared with control cases: median antithrombin III concentrations (240.4 vs 150.3 mg/mL; P=.002), median plasminogen activator inhibitor 1 concentrations (4.1 vs 7.1 ng/mL; P<.001), soluble Tie2 (13.5 vs 10.4 ng/mL; P=.02), soluble vascular endothelial growth factor receptor 2 (9.0 vs 5.9 ng/mL; P=.003). Conclusion Participants with placenta accreta spectrum had a unique and distinct plasma protein signature. Many cases of placenta accreta spectrum are not diagnosed antenatally, despite identified risk factors and improved imaging methods. Identification of plasma protein biomarkers could further improve the antenatal diagnosis of placenta accreta spectrum . The purpose of this study was to determine if women with placenta accreta spectrum have a distinct plasma protein profile compared with control subjects. We obtained plasma samples before delivery from 16 participants with placenta accreta spectrum and 10 control subjects with similar gestational ages (35.1 vs 35.5 weeks gestation, respectively). We analyzed plasma samples with an aptamer-based proteomics platform for alterations in 1305 unique proteins. Heat maps of the most differentially expressed proteins (T test, P<.01) were generated with matrix visualization and analysis software. Principal component analysis was performed with the use of all 1305 proteins and the top 21 dysregulated proteins. We then confirmed dysregulated proteins using enzyme-linked immunosorbent assay and report significant differences between placenta accreta spectrum and control cases (Wilcoxon-rank sum test, P<.05). Many of the top 50 proteins that significantly dysregulated in participants with placenta accreta spectrum were inflammatory cytokines, factors that regulate vascular remodeling, and extracellular matrix proteins that regulate invasion. Placenta accreta spectrum, with the use of the top 21 proteins, distinctly separated the placenta accreta spectrum cases from control cases (P<.01). Using enzyme-linked immunosorbent assay, we confirmed 4 proteins that were dysregulated in placenta accreta spectrum compared with control cases: median antithrombin III concentrations (240.4 vs 150.3 mg/mL; P=.002), median plasminogen activator inhibitor 1 concentrations (4.1 vs 7.1 ng/mL; P<.001), soluble Tie2 (13.5 vs 10.4 ng/mL; P=.02), soluble vascular endothelial growth factor receptor 2 (9.0 vs 5.9 ng/mL; P=.003). Participants with placenta accreta spectrum had a unique and distinct plasma protein signature." @default.
• W3011518421 created "2020-03-23" @default.
• W3011518421 creator A5000992292 @default.
• W3011518421 creator A5001348917 @default.
• W3011518421 creator A5009430860 @default.
• W3011518421 creator A5015914957 @default.
• W3011518421 creator A5018851209 @default.
• W3011518421 creator A5039534776 @default.
• W3011518421 creator A5042380319 @default.
• W3011518421 creator A5044850861 @default.
• W3011518421 creator A5053701327 @default.
• W3011518421 creator A5057970778 @default.
• W3011518421 creator A5059326304 @default.
• W3011518421 creator A5070196840 @default.
• W3011518421 creator A5074139274 @default.
• W3011518421 creator A5079758770 @default.
• W3011518421 creator A5081941917 @default.
• W3011518421 creator A5082987136 @default.
• W3011518421 date "2020-09-01" @default.
• W3011518421 modified "2023-10-18" @default.
• W3011518421 title "Placenta accreta spectrum: biomarker discovery using plasma proteomics" @default.
• W3011518421 cites W1538077234 @default.
• W3011518421 cites W1555293716 @default.
• W3011518421 cites W1559400249 @default.
• W3011518421 cites W1593139778 @default.
• W3011518421 cites W1604695494 @default.
• W3011518421 cites W1930595857 @default.
• W3011518421 cites W1931768946 @default.
• W3011518421 cites W1964898713 @default.
• W3011518421 cites W1970637953 @default.
• W3011518421 cites W1971792978 @default.
• W3011518421 cites W1990862686 @default.
• W3011518421 cites W1995033273 @default.
• W3011518421 cites W2002307675 @default.
• W3011518421 cites W2009456928 @default.
• W3011518421 cites W2020845827 @default.
• W3011518421 cites W2024611038 @default.
• W3011518421 cites W2035820496 @default.
• W3011518421 cites W2046996292 @default.
• W3011518421 cites W2054439472 @default.
• W3011518421 cites W2081596239 @default.
• W3011518421 cites W2083857553 @default.
• W3011518421 cites W2084373725 @default.
• W3011518421 cites W2084544217 @default.
• W3011518421 cites W2093766617 @default.
• W3011518421 cites W2112493515 @default.
• W3011518421 cites W2132366506 @default.
• W3011518421 cites W2140459348 @default.
• W3011518421 cites W2280205298 @default.
• W3011518421 cites W2462540433 @default.
• W3011518421 cites W2480575086 @default.
• W3011518421 cites W2565930577 @default.
• W3011518421 cites W2619876526 @default.
• W3011518421 cites W2624038863 @default.
• W3011518421 cites W2647461845 @default.
• W3011518421 cites W2789318673 @default.
• W3011518421 cites W2791467986 @default.
• W3011518421 cites W2800184935 @default.
• W3011518421 cites W2810464718 @default.
• W3011518421 cites W2883637015 @default.
• W3011518421 cites W2911867653 @default.
• W3011518421 cites W2912291084 @default.
• W3011518421 cites W2913759979 @default.
• W3011518421 cites W2920932433 @default.
• W3011518421 cites W2922143627 @default.
• W3011518421 cites W2948149017 @default.
• W3011518421 cites W2948812843 @default.
• W3011518421 cites W2953060245 @default.
• W3011518421 cites W3099018540 @default.
• W3011518421 cites W3105017384 @default.
• W3011518421 cites W4375905772 @default.
• W3011518421 doi "https://doi.org/10.1016/j.ajog.2020.03.019" @default.
• W3011518421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32199927" @default.
• W3011518421 hasPublicationYear "2020" @default.
• W3011518421 type Work @default.
• W3011518421 sameAs 3011518421 @default.
• W3011518421 citedByCount "37" @default.
• W3011518421 countsByYear W30115184212020 @default.
• W3011518421 countsByYear W30115184212021 @default.
• W3011518421 countsByYear W30115184212022 @default.
• W3011518421 countsByYear W30115184212023 @default.
• W3011518421 crossrefType "journal-article" @default.
• W3011518421 hasAuthorship W3011518421A5000992292 @default.
• W3011518421 hasAuthorship W3011518421A5001348917 @default.
• W3011518421 hasAuthorship W3011518421A5009430860 @default.
• W3011518421 hasAuthorship W3011518421A5015914957 @default.
• W3011518421 hasAuthorship W3011518421A5018851209 @default.
• W3011518421 hasAuthorship W3011518421A5039534776 @default.
• W3011518421 hasAuthorship W3011518421A5042380319 @default.
• W3011518421 hasAuthorship W3011518421A5044850861 @default.
• W3011518421 hasAuthorship W3011518421A5053701327 @default.
• W3011518421 hasAuthorship W3011518421A5057970778 @default.
• W3011518421 hasAuthorship W3011518421A5059326304 @default.
• W3011518421 hasAuthorship W3011518421A5070196840 @default.
• W3011518421 hasAuthorship W3011518421A5074139274 @default.
• W3011518421 hasAuthorship W3011518421A5079758770 @default.
• W3011518421 hasAuthorship W3011518421A5081941917 @default.
• W3011518421 hasAuthorship W3011518421A5082987136 @default.

• next